SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors debate the potential for a transformative buyout following reports of massive pharmaceutical M&A activity in the oncology space. Community discussions are highly polarized, with bulls highlighting the trial's prolonged survival timeline as evidence of therapeutic success, while bears express concern over the company's financial structure and the potential for a binary clinical outcome.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense community speculation as investors anticipate imminent Phase 3 VELA data, fueling intense M&A discussions and optimism that sonelokimab will emerge as a best-in-class treatment for hidradenitis suppurativa. The community is closely watching for a potential data release to coincide with upcoming investor presentations, which many believe could trigger a massive rerating event due to the drug's demonstrated efficacy and superior safety profile over existing competition.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda, which confirms that another major OEM has validated the company's solid-state battery technology after rigorous testing. The community is actively debating the significance of this partnership, weighing the long-term potential of the technology against frustrations over the lack of immediate commercial-scale revenue.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense investor attention following a significant clinical data release for Lupkynis and increased share accumulation by CEO Kevin Tang. While the community is actively debating the potential for an imminent buyout or strategic acquisition, sentiment remains divided between hopeful longs anticipating a catalyst-driven surge and skeptics frustrated by a lack of direct management communication.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to a significant partnership with Midjourney to integrate its ultrasound-on-chip technology into a new AI-powered full-body scanner. While the community is actively debating the stock's long-term potential as a semiconductor play versus immediate dilution risks and a 'sell-the-news' pullback, the stock has seen heightened volume and volatility as bulls look for a breakthrough of key resistance levels.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as market participants closely monitor geopolitical tensions in the Middle East and their potential impact on energy markets and interest rate sentiment. The community is actively debating the durability of the AI-driven tech rally amidst record market highs and ongoing economic uncertainty.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is seeing significant momentum as investors rotate into high-beta quantum stocks, fueled by bullish sentiment surrounding sector-wide commercialization and institutional interest. The community is actively discussing the stock's speculative upside, particularly in relation to its strong cash position and recent technical breakouts that have triggered increased short-squeeze speculation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors aggressively rotate capital into the semiconductor sector, driven by strong institutional demand for AI-focused infrastructure and data center expansion. The community is closely debating the sustainability of these gains, weighing cyclical memory market concerns against the long-term potential of chiplet architectures and quantum integration partnerships.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing significant market interest as investors pivot toward its long-term potential in edge AI, automotive, and data center infrastructure, moving beyond its traditional smartphone focus. The community is actively discussing upcoming catalysts like investor day, potential hyperscaler partnerships, and the stock's relative value compared to other high-flying semiconductor peers.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the semiconductor community highlights its critical role in advanced packaging and testing, viewed as a major bottleneck in the AI supply chain alongside players like TSMC and NVIDIA. Investors are actively discussing the company's long-term growth potential driven by its Arizona facility expansion and robust partnerships, despite current technical consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockTwits Web

Adagio Medical Holdings Inc.

ScamDeals.ru

@SearchFor911 my understanding is that maybe they get an acceptance of submission letter at the beginning of July. Then we wait for approval sometime in q4.

PLX_BULLS

StockTwits for iOS

 my understanding is that maybe they get an acceptance of submission letter at the beginning of July. Then we wait for approval sometime in q4.

Michael

@87trades 5th July would be Day45. Could be any day beginning at next week. FDA did not need all 45 days in the past. - PMA acceptance could be as soon as October, so early Q4, if everything goes well. 
 
Besides filing acceptance I would like to get a Gen2 enrollment update. They should finish enrollment before possible PMA decision.

 5th July would be Day45. Could be any day beginning at next week. FDA did not need all 45 days in the past. - PMA acceptance could be as soon as October, so early Q4, if everything goes well. 
 
Besides filing acceptance I would like to get a Gen2 enrollment update. They should finish enrollment before possible PMA decision.